The abstract is read at the publisher; the summary is JClub's.
Regulatory T cells (Tregs) are linked to persistent immunosuppression that limits immune checkpoint inhibitor responses, motivating non-co-signaling Treg-targeting strategies.
- Why it matters: Many patients do not respond to immune checkpoint inhibitors, and Treg-driven suppression in the tumor microenvironment is a key reason.
- What they did: This review summarizes rationale and clinical progress for non-co-signaling Treg approaches, including interleukin-2/CD25, transforming growth factor-beta, forkhead box P3, CD39/CD73 adenosine, and C-C motif chemokine receptor 4/8 pathways.
- The result: The field is expanding toward metabolic, cytokine, chemokine, and transcriptional targeting, plus improved biomarkers and engineering to enhance precision and durability across broader patient populations.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.